Healthleap Raises $38M to Deploy AI Hospital System That Flags At-Risk Patients

Funding and Company Overview

Healthleap, an artificial intelligence platform designed to identify hospitalized patients at risk of undiagnosed conditions, has secured $38 million across seed and Series A funding rounds. The funding structure includes an $8 million seed round co-led by Sequoia Capital and First Round Capital, followed by a $30 million Series A led by Hummingbird Ventures. Founded in South Africa in 2022 by siblings Jemima and Josiah Meyer, the company evolved from its initial focus on clinical nutrition tools to a broader AI-driven platform aimed at catching missed diagnoses in hospital settings.

How the Technology Works

Healthleap's core approach combines natural language processing with structured clinical data to surface at-risk patients. The platform integrates with hospital electronic health record systems and uses language models to extract meaningful clinical details from physicians' written notes—references to poor appetite, recent weight loss, muscle deterioration, or swallowing difficulties—alongside traditional data like lab results and vital signs. Each night, the system analyzes every adult inpatient's complete medical record and generates risk scores delivered to care teams the following morning through a dashboard integrated into existing workflows. Critically, the software does not diagnose patients but rather flags cases warranting closer clinical review.

Current Deployment and Market Traction

The platform is now operating across more than 50 hospitals, growing from just three hospital partners within the past year. Major health systems using Healthleap include Penn Medicine, Cedars-Sinai, Intermountain, Houston Methodist, and Emory Healthcare. The startup has developed screening programs for malnutrition, delirium, aspiration pneumonia, pressure ulcers, and readmission risk for congestive heart failure. Revenue has expanded more than tenfold over the past twelve months, though the company has not disclosed specific figures or valuation details.

Clinical and Financial Impact

Malnutrition emerged as an effective starting point for Healthleap's product roadmap, as research indicates 20 to 50 percent of hospitalized patients experience malnutrition—a condition that remains frequently undiagnosed despite its documented impact on recovery, wound healing, infection rates, and mortality. At the Hospital of the University of Pennsylvania, Healthleap's malnutrition program generated $23.8 million in annualized financial impact, comprising $6.3 million from additional reimbursement and $17.5 million from shortened hospital stays. The company employs an outcome-based pricing model alongside three-year contracts priced by licensed bed count. According to the founders, every customer to date has realized a minimum 5x return on investment, with some exceeding 20x annual returns, which Healthleap contractually validates using hospital finance teams' hard ROI attribution.

Future Growth Strategy

Healthleap intends to deploy the capital toward engineering, product development, sales, and customer success operations as it expands its condition-detection capabilities. The company aims ultimately to identify more than 40 major health conditions and extend its platform beyond inpatient hospital settings into outpatient clinics and home care environments.